<SEC-DOCUMENT>0001096906-23-002058.txt : 20231026
<SEC-HEADER>0001096906-23-002058.hdr.sgml : 20231026
<ACCEPTANCE-DATETIME>20231026153011
ACCESSION NUMBER:		0001096906-23-002058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231026
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231026
DATE AS OF CHANGE:		20231026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		231349944

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20231026.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD4CR2GW]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D231026' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D231026' id='fact2'>false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20231026.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D231026'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-10-26</i:startDate>
<i:endDate>2023-10-26</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:14pt Times New Roman;margin:0;text-align:center'><b>UNITED STATES </b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'><b>Washington, D.C. &#160;20549</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>FORM <ix:nonNumeric name='dei:DocumentType' contextRef='D231026' escape='true'>8-K</ix:nonNumeric></b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>CURRENT REPORT</b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;text-align:center'><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>Date of Report (date of earliest event reported): &#160;<ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D231026' format='ixt:datemonthdayyearen'>October 26, 2023</ix:nonNumeric></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:14pt'><b><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D231026' escape='true'>UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D231026' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></p>
</td><td valign='top' style='width:2.6%'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D231026' escape='true'>000-12575</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:2.58%'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D231026' escape='true'>87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of</p>
</td><td valign='top' style='width:2.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Commission File Number)</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(IRS Employer</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>incorporation or organization)</p>
</td><td valign='top' style='width:2.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>Identification No.)</p>
</td></tr>
<tr><td valign='top' style='width:31.62%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D231026' escape='true'>7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:2.58%'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D231026' escape='true'>Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D231026' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:2.58%'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D231026' escape='true'>84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices)</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Zip code)</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0'>Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b>Phone: </b><b>(</b><b><ix:nonNumeric name='dei:CityAreaCode' contextRef='D231026' escape='true'>801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D231026' escape='true'>566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:65.82%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.58%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:31.6%'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:12pt Times New Roman;margin:0;text-align:center'><b>n/a</b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:100%;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:WrittenCommunications' contextRef='D231026' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:SolicitingMaterial' contextRef='D231026' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementTenderOffer' contextRef='D231026' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementIssuerTenderOffer' contextRef='D231026' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Emerging growth company <ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D231026' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:11pt Times New Roman;margin:0'><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:72pt'>Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated October 26, 2023. &#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:72pt'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:72pt'>The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0'><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>The following is filed as an exhibit to this report: &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Exhibit</b></p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Number*</b></p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Title of Document</b></p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Location</b></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b>Item 99.1</b></p>
</td><td valign='top' style='background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><span style='font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex99z1.htm' style='text-decoration:none'>Financial information for Utah Medical Prod</a><a href='utmd_ex99z1.htm' style='text-decoration:none'>ucts, Inc. for the three and nine months ended September</a><a href='utmd_ex99z1.htm' style='text-decoration:none'> 30, 2023 and forward-looking statements relating to 2023 and beyond as present</a><a href='utmd_ex99z1.htm' style='text-decoration:none'>ed in a press release dated October 26</a><a href='utmd_ex99z1.htm' style='text-decoration:none'>, 2023.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:12.56%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:69.22%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:12.98%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>This filing</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>_______________________________________</p>
<p style='font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify'><kbd style='position:absolute;font:9pt Times New Roman;margin-left:-18pt'>*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><b>SIGNATURES</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Dated:  October 26, 2023</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>By:</p>
</td><td valign='top' style='width:218.05pt;border-bottom:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:218.05pt;border-top:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND FORWARD-LOOKING STATEMENTS RELATING TO 2023 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED OCTOBER 26, 2023.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD4CR2GW]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:11pt><B>EXHIBIT 99.1</B></FONT><B> </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2023</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:50%><P style='font:11pt Times New Roman;margin:0'>Contact: Brian Koopman (801) 566-1200</P>
</TD><TD valign=top style=width:50%><P align=right style='font:11pt Times New Roman;margin:0'>October 26, 2023</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;Utah Medical Products, Inc. [Nasdaq: UTMD], despite a difficult third calendar quarter (3Q), achieved financial results for nine months (9M) 2023 consistent with those anticipated in its beginning of year projections. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>The following is a summary comparison of 3Q and first nine months (9M) of calendar 2023 with 3Q and 9M 2022 income statement measures:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:53.8%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>3Q</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>9M</P>
</TD></TR>
<TR><TD valign=top style=width:53.8%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2023 to 2022 Comparison</FONT></P>
</TD><TD valign=top style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(July&#8211;September)</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(January-September)</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:53.8%><P style='font:11pt Times New Roman;margin:0'>Revenues (Sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>(3%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>(2%)</P>
</TD></TR>
<TR><TD valign=top style=width:53.8%><P style='font:11pt Times New Roman;margin:0'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>(10%)</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>(4%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:53.8%><P style='font:11pt Times New Roman;margin:0'>Operating Income (OI):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>(23%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>(13%)</P>
</TD></TR>
<TR><TD valign=top style=width:53.8%><P style='font:11pt Times New Roman;margin:0'>Income Before Tax (EBT):</P>
</TD><TD valign=top style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>(10%)</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>- </P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:53.8%><P style='font:11pt Times New Roman;margin:0'>Net Income (NI):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>(8%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+ 4%</P>
</TD></TR>
<TR><TD valign=top style=width:53.8%><P style='font:11pt Times New Roman;margin:0'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:21.2%><P align=center style='font:11pt Times New Roman;margin:0'>(8%)</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+ 4%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Worldwide (WW) consolidated sales in 3Q 2023 were $450 lower than in 3Q 2022, and were $816 lower in 9M 2023 compared to 9M 2022. &nbsp;This essentially was because 3Q 2023 biopharmaceutical OEM sales were $1,217 lower than in 3Q 2022, and were $1,847 lower in 9M 2023 compared to 9M 2022. &nbsp;Sales invoiced in foreign currencies, which did not include any biopharmaceutical OEM sales, represented 25% of total WW consolidated 3Q 2023 sales (when expressed in USD) and 29% of 9M 2023 total WW consolidated sales. Constant currency sales, U.S. dollar sales using the same foreign currency exchange (FX) rates as in the prior year&#8217;s same periods, were $155 higher in 3Q 2023 as a result of a stronger EUR and GBP compared to 3Q 2022, but $33 lower for 9M 2023 because of a weaker AUS and CAD, despite a stronger EUR, for 9M 2023 year-to-date. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Profit margins in 3Q and 9M 2023 compared to 3Q and 9M 2022 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:40.14%><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>3Q 2023 </P>
</TD><TD valign=top style=width:14.98%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>3Q 2022</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>9M 2023</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>9M 2022</P>
</TD></TR>
<TR><TD valign=top style=width:40.14%><P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>&nbsp;</P>
</TD><TD valign=top style='width:14.96%;border-bottom:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>(Jul &#8211;&nbsp;Sep)</P>
</TD><TD valign=top style='width:14.98%;border-bottom:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>(Jul &#8211;&nbsp;Sep)</P>
</TD><TD valign=top style='width:14.96%;border-bottom:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>(Jan &#8211;&nbsp;Sep)</P>
</TD><TD valign=top style='width:14.96%;border-bottom:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>(Jan &#8211;&nbsp;Sep)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.14%><P style='font:11pt Times New Roman;margin:0'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:14.96%;border-top:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>58.8%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:14.98%;border-top:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>63.2% </P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:14.96%;border-top:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>60.5%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:14.96%;border-top:0.75pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>61.7%</P>
</TD></TR>
<TR><TD valign=top style=width:40.14%><P style='font:11pt Times New Roman;margin:0'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>31.7%</P>
</TD><TD valign=top style=width:14.98%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>39.7%</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.9%</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>38.0%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.14%><P style='font:11pt Times New Roman;margin:0'>EBT Margin (EBT/ sales):</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>38.2%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.98%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>41.2%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>39.8%</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>38.9%</P>
</TD></TR>
<TR><TD valign=top style=width:40.14%><P style='font:11pt Times New Roman;margin:0'>Net Income Margin (NI/ sales):</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>31.5%</P>
</TD><TD valign=top style=width:14.98%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>33.0%</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>32.6%</P>
</TD><TD valign=top style=width:14.96%><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt'>30.8%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT = Income Before Taxes = (Operating Income + Non-Operating Income)</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In 9M 2023, UTMD achieved its targeted GP Margin (GPM), although somewhat lower than in 9M 2022 due to planned higher manufacturing overhead costs with less absorption because of lower sales. &nbsp;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. The lower 3Q 2023 GPM was a good example of this. In addition to the lower absorption of higher overhead </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>costs, the Company had an unfavorable product mix due to much higher foreign distributor sales compared to 3Q 2022, and experienced higher than normal medical expenses in its self-funded U.S. health care plan. &nbsp;International distributor prices are lower than prices of products sold directly to medical facilities WW.</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In addition to the 4.4 percentage point lower 3Q 2023 GPM and the 1.2 percentage point lower 9M 2023 GPM, the OI Margins in both periods were reduced another 2.8 percentage points by 2023 litigation expenses captured in General &amp; Administrative (G&amp;A) expenses. Due primarily to interest earned on cash balances included in Non-operating income, UTMD was able to achieve higher EBT, NI and EPS in 9M 2023 compared to the prior 9M 2022.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s September 30, 2023 Balance Sheet, in the absence of debt, continued to strengthen with total assets up $0.8 million from the end of 2022. Ending Cash and Investments were $88.2 million on September 30, 2023 compared to $75.1 million on December 31, 2022, after paying $3.2 million in cash dividends to stockholders and purchasing $0.5 million in new Property and Equipment in 9M 2023. &nbsp;UTMD&#8217;s cash balance increased $3.62/ outstanding share at September 30, 2023 from the end of 2022 with a 4% increase in Net Income, while the stock price declined $14.53/ share. Stockholders&#8217; Equity (SE) increased $9.4 million in the nine-month period from December 31, 2022 despite the fact that $3.2 million in dividends reduced SE. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 3Q 2023 compared to the end of calendar year 2022 and the end of 3Q 2022 follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-23</FONT></P>
</TD><TD valign=top style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-22</FONT></P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-22</FONT></P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>1.22134</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>1.20771</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1.1%</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1.11303</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>9.7%</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>1.05841</P>
</TD><TD valign=top style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>1.06940</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(1.0%)</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.97878</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>8.1%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>0.64494</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>0.68050</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>(5.2%)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.64366</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>0.2%</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:13.46%><P align=center style='font:11pt Times New Roman;margin:0'>0.73873</P>
</TD><TD valign=top style=width:14.9%><P align=center style='font:11pt Times New Roman;margin:0'>0.73899</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>0.72722</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>1.6%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> -<FONT style='border-bottom:1px solid #000000'>3Q 2023</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total WW UTMD consolidated 3Q 2023 sales were $450 (3.0%) lower than in 3Q 2022. WW constant currency sales were $605 (4.7%) lower. U.S. domestic sales were 15.7% lower (obviously without any FX impact), and outside the U.S. (OUS) sales were 20.8% higher. Without the benefit of a weaker USD in converting foreign currency sales, 3Q 2023 OUS sales were 17.2% higher.  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 3Q 2023 were $7,265 compared to $8,615 in 3Q 2022. &nbsp;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and acquisition history. Domestic direct other device sales, representing 56% of total domestic sales, were $9 (+0.2%) higher in 3Q 2023 than in 3Q 2022. Domestic OEM sales, representing 28% of total domestic sales, were $1,019 (33.4%) lower, including $1,103 lower U.S. biopharmaceutical OEM sales. Direct Filshie device sales, representing 16% of total domestic sales, were $341 (23.0%) lower in 3Q 2023 compared to 3Q 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS sales in 3Q 2023 were 20.8% higher at $5,240 compared to $4,340 in 3Q 2022. The increase in USD-denominated OUS sales was leveraged as a result of a weaker USD relative to the EUR and GBP, which added $155 to OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies in constant currency terms. FX rates for income statement purposes are transaction-weighted averages. The </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>weighted-average FX rates from the applicable foreign currency to USD during 3Q 2023 and 3Q 2022 for revenue purposes follow:</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>3<FONT style='border-bottom:1px solid #000000'>Q 2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>3<FONT style='border-bottom:1px solid #000000'>Q 2022</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2669</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.1760</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+ 7.7%</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0711</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0040</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+ 6.7%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6572</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6828</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;3.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7462</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7663</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;2.6%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The weighted average favorable FX rate difference impact on 3Q 2023 foreign currency OUS sales was 5.2%, increasing reported USD sales by $155 relative to the same foreign currency sales in 3Q 2022. &nbsp;In constant currency terms, foreign currency sales in 3Q 2023 were 17.2% higher than in 3Q 2022. The portion of OUS sales invoiced in foreign currencies in USD terms were 25.0% of total consolidated 3Q 2023 sales compared to 19.3% in 3Q 2022. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &nbsp;Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Direct to end-user foreign currency OUS 3Q 2023 sales in USD terms were 19.6% higher in Ireland, 21.6% lower in Canada, 8.2% higher in France, 30.8% lower in AUS/NZ and 17.2% higher in the UK than in 3Q 2022. Sales to OUS distributors/ international OEM (including biopharmaceutical) customers were 35.5% higher in 3Q 2023 than in 3Q 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>9M 2023</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 9M 2023 UTMD WW consolidated sales were $816 (2.1%) lower than in 9M 2022. Constant currency 9M 2023 sales were $33 (+0.1%) lower due to a slightly stronger USD year-to-date. U.S. domestic sales were 12.1% lower and OUS sales were 15.0% higher.   </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 9M 2023 were $21,467 compared to $24,429 in 9M 2022. &nbsp;Direct other device sales, representing 53% of total domestic sales, were $689 (5.7%) lower in 9M 2023 than in 9M 2022. &nbsp;The lower direct other device sales year-to-date resulted from continued supply chain disruption. Domestic OEM sales, representing 30% of total domestic sales, were $1,919 (22.8%) lower. The biopharmaceutical portion of domestic OEM sales were $1,963 (28.2%) lower. &nbsp;Direct domestic Filshie device sales, representing 17% of total domestic sales, were $354 (9.0%) lower in 9M 2023 compared to 9M 2022 due to lower demand. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS sales in 9M 2023 were 15.0% higher at $16,424 compared to $14,278 in 9M 2022. The increase in 9M 2023 USD-denominated OUS sales was only slightly diminished as a result of a stronger USD which subtracted $33 from OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies (in constant currency terms). &nbsp;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 9M 2023 and 9M 2022 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2434</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2488</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;0.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0790</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0672</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+ 1.1%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6708</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7058</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;5.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7432</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7797</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;4.7%)</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>The weighted-average unfavorable impact on 9M 2023 foreign currency OUS sales was just 0.3%, reducing reported USD sales by $33 relative to the same foreign currency sales in 9M 2022. &nbsp;In constant currency terms, OUS sales in 9M 2023 were 15.3% higher than in 9M 2022. The portion of OUS sales invoiced in foreign currencies in USD terms was 28.8% of total consolidated 9M 2023 sales compared to 23.9% in 9M 2022. Direct to end-user foreign currency OUS 9M 2023 sales in USD terms were 5.3% higher in Ireland, 14.1% lower in Canada, 9.5% higher in France, 21.7% higher in the UK and 18.2% lower in AUS/NZ. Sales to OUS distributors/OEM (including biopharmaceutical) customers were 21.2% higher in 9M 2023 than in 9M 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Since shipments to OEM customers and OUS distributors typically have long lead times, the current order backlog added to 9M 2023 sales results for those segments provides a fair estimate for 2023 sales as a whole, barring new unresolved raw material supply constraints and further third-party sterilization capacity limits. Based on the current backlog, management expects that WW biopharmaceutical OEM sales to its largest customer will be about $3 million lower in 2023 than in 2022, representing about 17% of 2023 total consolidated sales compared to 22% in 2022. &nbsp;This projection is consistent with management&#8217;s beginning of year 2023 sales estimates, and suggests a net total annual 2023 consolidated sales decline of about $2 million. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers from revenues. UTMD&#8217;s GP was $827 (10.1%) lower in 3Q 2023 than in 3Q 2022, and $929 (3.9%) lower in 9M 2023 than in 9M 2022. UTMD price increases to customers since early 2022 were substantially lower than its continued cost increases, with continued &#8220;sticky&#8221; inflation. &nbsp;Although direct labor productivity remained consistent with the past, raw material costs continued to increase and higher manufacturing overhead costs were less absorbed by lower revenues. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. &nbsp;OI in 3Q 2023 was $3,969 compared to $5,141 in 3Q 2022, a $1,171 (22.8%) decline; and was $12,833 in 9M 2023 compared to $14,720 in 9M 2022, a $1,887 (12.8%) decline. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 3Q and 9M 2023 compared to the same periods in 2022 by OE category:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:12.6%><P style='font:11pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:11.44%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2023</FONT></P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR> <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2023</FONT></P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:12.6%><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'>$ 417</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.3</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 373</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.9</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 1,209</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.2</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 1,066</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.7</P>
</TD></TR>
<TR><TD valign=bottom style=width:12.6%><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=bottom style=width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'>2,835</P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>22.7</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,560</P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.8</P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;8,484</P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>22.4</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;7,713</P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>19.9</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:12.6%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;138</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp; 112</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;0.8</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;&nbsp;414</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.1</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp; &nbsp;&nbsp;370</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.0</FONT></P>
</TD></TR>
<TR><TD valign=bottom style=width:12.6%><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=bottom style=width:11.44%><P align=center style='font:11pt Times New Roman;margin:0'>3,390</P>
</TD><TD valign=bottom style='width:9.28%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>27.1</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,045</P>
</TD><TD valign=bottom style='width:11.1%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>23.5</P>
</TD><TD valign=bottom style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 10,107</P>
</TD><TD valign=bottom style='width:11.1%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>26.7</P>
</TD><TD valign=bottom style='width:11.12%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;9,149</P>
</TD><TD valign=bottom style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>23.6</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Changes in foreign currency exchange rates did not have a significant impact on consolidated financial results in 2023. &nbsp;A stronger EUR and GBP in 3Q<FONT style=font-family:Symbol>&#32;</FONT>2023 helped increase OUS S&amp;M expense by $3 and OUS G&amp;A expense by $51. An average slightly stronger USD for 9M 2023, reduced OUS S&amp;M expenses by $4, OUS G&amp;A expenses by $26 and OUS R&amp;D expenses by $1. The following table summarizes &#8220;constant currency&#8221; OE in 3Q and 9M 2023 compared to the same periods in 2022 by OE category:</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:21.98%><P style='font:11pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:19.92%><P align=center style='font:11pt Times New Roman;margin:0'>3Q 2023 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:19.38%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=bottom style='width:19.38%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>9M 2023 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style='width:19.36%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:21.98%><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:19.92%><P align=center style='font:11pt Times New Roman;margin:0'>$ 414</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:19.38%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 373</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:19.38%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 1,213</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:19.36%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 1,066</P>
</TD></TR>
<TR><TD valign=bottom style=width:21.98%><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=bottom style=width:19.92%><P align=center style='font:11pt Times New Roman;margin:0'>2,784</P>
</TD><TD valign=bottom style='width:19.38%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,560</P>
</TD><TD valign=bottom style='width:19.38%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;8,510</P>
</TD><TD valign=bottom style='width:19.36%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;7,713</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:21.98%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:19.92%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;138</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:19.38%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp; 112</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:19.38%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp; 415</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:19.36%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp; 370</FONT></P>
</TD></TR>
<TR><TD valign=bottom style=width:21.98%><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=bottom style=width:19.92%><P align=center style='font:11pt Times New Roman;margin:0'>3,336</P>
</TD><TD valign=bottom style='width:19.38%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3,045</P>
</TD><TD valign=bottom style='width:19.38%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 10,138</P>
</TD><TD valign=bottom style='width:19.36%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;9,149</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>S&amp;M and R&amp;D expenses were higher primarily as a result of cost-of-living adjustments to employee salaries. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>A division of G&amp;A expenses by location follows. G&amp;A expenses include non-cash expenses from the amortization of IIA associated with the Filshie Clip System, which is also separated out below:  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2023</FONT></P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2023</FONT></P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>$ 504</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 4.0</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> $ 467</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.6</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$1,484</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.9</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$1,497</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3.9</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>8.8</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.5</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3,316</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.8</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;3,316</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8.6</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;171</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;132</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;498</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;428</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; US:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;912</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;710</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,752</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,018</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;74</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;73</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;227</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;224</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;38</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;39</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;107</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;124</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp; 31</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp; 34</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;100</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;106</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>2,835</P>
</TD><TD valign=bottom style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>22.7</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,560</P>
</TD><TD valign=bottom style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.8</P>
</TD><TD valign=bottom style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>8,484</P>
</TD><TD valign=bottom style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>22.4</P>
</TD><TD valign=bottom style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>7,713</P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>19.9</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Although the IIA amortization expense in either USD or GBP, depending on where expensed, was the same as in the prior year&#8217;s same periods, the 3Q 2023 OI margin was diluted by 0.7 percentage points, and the 9M 2023 OI margin was diluted by 0.2 percentage points, due to a lower sales denominator and the GBP FX rate difference. Non-cash IIA amortization expense was 57% of total G&amp;A expenses in both 3Q 2023 and 9M 2023. &nbsp;Litigation expenses, included in the Other-US G&amp;A Expense category above, were about 2.8% of sales in both 3Q 2023 and 9M 2023. &nbsp;Litigation expenses were 1.4% of sales in 3Q 2022 and 1.1% of sales in 9M 2022. &nbsp;In other words, higher litigation expenses reduced UTMD&#8217;s OI margin by another 1.4 percentage points in 3Q 2023, and another 1.7 percentage points in 9M 2023.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS G&amp;A expenses in USD terms were $818 in 3Q 2023 compared to $745 in 3Q 2022. OUS G&amp;A expenses were $2,416 in 9M 2023 compared to $2,379 in 9M 2022. The constant currency table below shows how the changes in FX rates affected reported OUS G&amp;A expenses for 3Q 2023 ($51 higher) and 9M 2023 ($26 lower):</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:12.48%><P style='font:11pt Times New Roman;margin:0'>3Q 2023 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'>9M 2023 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=bottom style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>$ 468</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'>$ 467</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'>$1,471</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'>$1,497</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;159</P>
</TD><TD valign=bottom style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;132</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;494</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;428</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;69</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;73</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;230</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;224</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;39</P>
</TD><TD valign=bottom style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;39</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;101</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;124</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom bgcolor=#CCEEFF style=width:19.96%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;32</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;34</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;94</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;106</FONT></P>
</TD><TD valign=bottom bgcolor=#CCEEFF style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom style=width:19.96%><P style='font:10pt Times New Roman;margin:0'>Total OUS G&amp;A:</P>
</TD><TD valign=bottom style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;767</P>
</TD><TD valign=bottom style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;745</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2,390</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2,379</P>
</TD><TD valign=bottom style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Summary explanation for changes in OI Margin from prior year&#8217;s same periods:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style='border-collapse:collapse;width:100%;border:0.5pt solid #000000'><TR><TD valign=top style='width:55.06%;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Expense Category</FONT></P>
</TD><TD valign=top style='width:21.06%;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3Q %- Point<FONT style='border-bottom:1px solid #000000'> Reduction</FONT></P>
</TD><TD valign=top style='width:23.88%;border:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>9M %- Point<FONT style='border-bottom:1px solid #000000'> </FONT><BR><FONT style='border-bottom:1px solid #000000'>Reduction</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:55.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>GPM:</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:21.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>4.4</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:23.88%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.2</P>
</TD></TR>
<TR><TD valign=top style='width:55.06%;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Litigation Expense (G&amp;A)</P>
</TD><TD valign=top style='width:21.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.4</P>
</TD><TD valign=top style='width:23.88%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.7</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:55.06%;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>IIA Amortization Expense (G&amp;A)</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:21.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.7</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:23.88%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.2</P>
</TD></TR>
<TR><TD valign=top style='width:55.06%;border:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>All Other Operating Expenses</P>
</TD><TD valign=top style='width:21.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1.5</FONT></P>
</TD><TD valign=top style='width:23.88%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1.0</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:55.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>Reduction in OI Margin:</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:21.06%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8.0</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:23.88%;border:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>4.1</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 3Q 2023 EBT was $4,781 (38.2% of sales) compared to $5,339 (41.2% of sales) in 3Q 2022. Consolidated 9M 2023 EBT was $15,072 (39.8% of sales) compared to $15,068 (38.9% of sales) in 9M 2022. The improvement in 9M EBT was due to higher net NOI. &nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Negative NOE is NOI. &nbsp;Net NOI in 3Q 2023 was $811 compared to $198 NOI in 3Q 2022. Net NOI in 9M 2023 was $2,239 compared to $348 NOI in 9M 2022. UTMD realized a $7 remeasured currency balance loss in both 9M 2023 and 9M 2022. With higher cash balances and interest rates in 9M 2023 compared to 9M 2022, UTMD received $1,826 more in WW interest income. NOI generated in Ireland from renting unused warehouse space to a third party yielded a further increase in 9M 2023 NOI compared to 9M 2022. &nbsp;   &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2023 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) was $6,604 compared to $7,111 in 3Q 2022. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Adjusted consolidated EBITDA was $20,520 in 9M 2023 compared to $20,487 in 9M 2022. Adjusted consolidated EBITDA for the previous four calendar quarters (TTM) was $27,924 as of September 30, 2023. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 52.8% in 3Q 2023 compared to 54.9% in 3Q 2022, reflecting the lower 3Q 2023 GPM. &nbsp;UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 54.2% in 9M 2023 compared to 52.9% in 9M 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance during a difficult economic period of time. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2023</FONT></P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2023</FONT></P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>$4,781</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$5,339</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$15,072</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>$15,068</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>155</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>152</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>465</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>454</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>503</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>467</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,484</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>1,497</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>3,316</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>3,316</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'> 8</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>24</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>24</P>
</TD></TR>
<TR><TD valign=top style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>53</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>38</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>152</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>121</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:47.9%><P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:11.48%><P align=right style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:13.54%><P align=center style='font:11pt Times New Roman;margin:0;margin-left:36pt'>-</P>
</TD></TR>
<TR><TD valign=top style='width:47.9%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:11.48%;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> (1)</P>
</TD><TD valign=top style='width:13.54%;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>7</P>
</TD><TD valign=top style='width:13.54%;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>7</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style='width:47.9%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:11.48%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$6,604</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$7,111</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$20,520</P>
</TD><TD valign=top bgcolor=#CCEEFF style='width:13.54%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$20,487</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 3Q 2023 of $3,935 (31.5% of sales) was 8.1% lower than NI of $4,280 (33.0% of sales) in 3Q 2022. NI in 9M 2023 of $12,349 (32.6% of sales) was 3.6% higher than NI of $11,918 (30.8% of sales) in 9M 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The average consolidated income tax provisions (as a % of the same period EBT) in 3Q 2023 and 3Q 2022 were 17.7% and 19.8% respectively, and were 18.1% and 20.9% in 9M 2023 and 9M 2022 respectively. The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. In addition, a portion of UTMD&#8217;s 2023 NOI generated from interest on high grade tax-exempt municipal bonds helped reduce the overall income tax provision rate. UTMD has consistently paid millions of dollars in income taxes annually. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 3Q 2023 were $1.081 compared to $1.178 in 3Q 2022, an 8.2% decrease. Diluted EPS in 9M 2023 were $3.394 compared to diluted EPS of $3.265 in 9M 2022, a 4.0% increase. Diluted shares were 3,638,723 in 3Q 2023 compared to 3,634,235 in 3Q 2022. The higher diluted shares in 3Q 2023 were the result of exercise of employee options. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The number of shares used for calculating 3Q 2023 EPS was higher than September 30, 2023 actual outstanding shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. Outstanding shares at the end of 3Q 2023 were 3,629,525 compared to 3,627,767 at the end of calendar year 2022. The difference was due to 1,758 shares in employee option exercises during 9M 2023. For comparison, actual outstanding shares were 3,625,195 at the end of 3Q 2022. The total number of outstanding unexercised employee and outside director options at September 30, 2023 was 65,301 at an average exercise price of $73.83, including shares awarded but not yet vested. &nbsp;This compares to 49,895 unexercised option shares at the end of 3Q 2022 at an average exercise price of $69.00/ share, including shares awarded but not vested. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The number of shares added as a dilution factor for 3Q 2023 was 9,309 compared to 9,220 in 3Q 2022. The number of shares added as a dilution factor for 9M 2023 was 9,918 compared to 9,424 in 9M 2022. In October 2022, 20,600 option shares were awarded to 40 employees at an exercise price of $82.60. &nbsp;No options have been awarded in 2023. &nbsp;UTMD paid $1,071 ($0.295/share) in dividends to stockholders in 3Q 2023 compared to $1,051 ($0.290/ share) paid in 3Q 2022. Dividends paid to stockholders during 3Q 2023 were 27% of 3Q 2023 NI. UTMD paid $3,211 ($0.295/share) in dividends to stockholders in 9M 2023 compared to $2,111 ($0.290/ share) paid in 9M 2022. The difference was due to an earlier payment of a special dividend at the end of 2021 instead of in 1Q 2022. No UTMD shares have been purchased in </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>the open market in 2023. In 2Q 2022, the Company purchased 30,105 UTMD shares at an average cost of $82.88/ share. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s closing share price at the end of 3Q 2023 was $86.00, down from the closing price of $93.20 three months earlier at the end of 2Q 2023, and the closing price of $100.53 nine months earlier at the end of 2022. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At September 30, 2023, UTMD&#8217;s cash and investments increased $13,157 to $88,209 from $75,052 at the end of 2022, despite using cash during 9M 2023 to pay $3,211 in dividends to stockholders and $549 to purchase new manufacturing equipment, plus changes in working capital. The net increase in cash was provided by UTMD&#8217;s excellent operating 9M EBITDA of $20,520. At September 30, 2023, Net Intangible Assets decreased to 14.5% of total consolidated assets from 19.2% on December 31, 2022. &nbsp;The 2019 $21,000 purchase of remaining exclusive U.S. distribution rights for the Filshie Clip System will be fully amortized in October. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Financial ratios as of September 30, 2023 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 24.4&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 3Q 2023 sales activity) = 24.7&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 3Q 2023 average inventory and CGS) = 2.1&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2023 YTD ROE (before dividends) = 14%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC. &nbsp;UTMD&#8217;s 3Q 2023 SEC Form 10-Q will be filed on or before November 14, 2023, and can be accessed on <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Third Quarter (three months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2023</FONT></P>
</TD><TD valign=top style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2022</FONT></P>
</TD><TD valign=top style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>$ 12,505</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>$12,955</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>( 3.5%)</P>
</TD></TR>
<TR><TD valign=top style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>7,359</P>
</TD><TD valign=top style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>8,186</P>
</TD><TD valign=top style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>(10.1%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>3,969</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>5,141</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>(22.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>4,781</P>
</TD><TD valign=top style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>5,339</P>
</TD><TD valign=top style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>(10.5%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>3,935</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>4,280</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>( 8.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share (US GAAP)</P>
</TD><TD valign=top style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>$1.081</P>
</TD><TD valign=top style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>$ 1.178</P>
</TD><TD valign=top style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>( 8.2%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:38.9%><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:18.7%><P align=right style='font:10pt Times New Roman;margin:0'>3,639</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:19.5%><P align=right style='font:10pt Times New Roman;margin:0'>3,634</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:22.9%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, First Nine Months (nine months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2023</FONT></P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2022</FONT></P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>$ 37,891</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>$ 38,707</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;2.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>22,940</P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>23,869</P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>( &nbsp;3.9%)</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>12,833</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>14,720</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>(12.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>15,072</P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>15,068</P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>12,349</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>11,918</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>3.6%</P>
</TD></TR>
<TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>EPS (US GAAP)</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>$ 3.394</P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>$ 3.265</P>
</TD><TD valign=top style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>4.0%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>3,638</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>3,650</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:21.46%><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2023</FONT></P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2023</FONT></P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2022</FONT></P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2022</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>$88,209</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>$84,619</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>$75,052</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>$69,511</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>3,487</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>3,603</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>5,538</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>6,034</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>9,709</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>10,118</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>8,814</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>8,310</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>442</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>467</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>515</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>387</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>101,847</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>98,807</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>89,919</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>84,242</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>10,347</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>10,541</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>10,224</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>10,257</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>19,049</FONT></P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>21,127</FONT></P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>23,731</FONT></P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>23,914</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>$131,243</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>$130,475</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>$123,874</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>$118,413</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;511</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;1,336</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;1,218</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;1,289</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>419</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>419</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>419</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:18pt'>220 </P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,247</FONT></P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,389</FONT></P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,323</FONT></P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,760</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$4,177</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$5,144</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$5,960</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$6,269</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>1,196</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>1,370</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>1,513</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>1,479</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>305</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>315</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>341</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>354</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>1,256</P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>1,256</P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>1,256</P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>1,675</P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>607</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>628</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>549</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>450</P>
</TD></TR>
<TR><TD valign=top style=width:40.82%><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>123,702</FONT></P>
</TD><TD valign=top style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>121,762</FONT></P>
</TD><TD valign=top style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>114,255</FONT></P>
</TD><TD valign=top style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>108,186</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#CCEEFF style=width:40.82%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.36%><P align=right style='font:10pt Times New Roman;margin:0'>$131,243</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.18%><P align=right style='font:10pt Times New Roman;margin:0'>$130,475</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:14.62%><P align=right style='font:10pt Times New Roman;margin:0'>$123,874</P>
</TD><TD valign=top bgcolor=#CCEEFF style=width:15.02%><P align=right style='font:10pt Times New Roman;margin:0'>$118,413</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20231026_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD4CR2GW]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20231026"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20231026.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20231026_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD4CR2GW]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20231026"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20231026_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD4CR2GW]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20231026"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20231026.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20231026.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD4CR2GW]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:fil='http://utahmed.com/20231026' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://utahmed.com/20231026' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20231026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20231026_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20231026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import namespace='http://xbrl.sec.gov/dei/2023' schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2023' schemaLocation='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140605766230640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Oct. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>utmd-20231026_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20231026.xsd" xlink:type="simple"/>
    <context id="D231026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-10-26</startDate>
            <endDate>2023-10-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D231026" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D231026" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D231026">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D231026">2023-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D231026">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D231026">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D231026">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D231026">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D231026">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D231026">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D231026">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D231026">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D231026">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D231026">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D231026">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D231026">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D231026">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D231026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D231026">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ Q7M:5Y>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,5[6E>']TG1XP,  )<.   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #%>UI7GZ ;\+$"  #B#   #0              @ $F#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,5[6E>7BKL<P    !,"   +
M  "  0(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,5[6E<<.&7J/P$  #P"
M   /              "  >L/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #%>UI7)!Z;HJT   #X 0  &@              @ %7$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #%>UI799!YDAD!  #/ P
M$P              @ $\$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  "&$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20231026.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20231026.htm">utmd-20231026.htm</File>
    <File>utmd-20231026.xsd</File>
    <File>utmd-20231026_def.xml</File>
    <File>utmd-20231026_lab.xml</File>
    <File>utmd-20231026_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20231026.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20231026",
   "dts": {
    "inline": {
     "local": [
      "utmd-20231026.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20231026.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20231026_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20231026_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20231026_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D231026",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20231026.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D231026",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20231026.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20231026/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-23-002058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-23-002058-xbrl.zip
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MZ%[S#H(]S2G4MVC"(4(ED2%S,:KQ" \(5U*'S-!M?]GXEH\I9YM%Y]E&-:L
MFLJ5M#EF\>=G1HGL>&Z<CEDHOY)Q/HO0;6S"'S= L#06$;@PO52^4N!K&B*&
MA=^H(;PUO!.F)W"UH%@8B1L$CN[IHZ*#Y5'6$\5_*__U5+G8F3^PU_,'I]QG
M\ Y\^UJ^ )9\ANT42H7U+/\3E/&'X'J7WK72];*K%6&#*2B7#"N7=TH8Q6[L
M?5^*=]K3FH]ANX!P/2)_0;0N/9[$\Z+_ZMW67D,,AUQBFIR@"I)$ /9?OR/;
M:W6N2',8^F+$HI<NIGS666EIC:YIP/_1]QM,UG<JI3]*<#5OBTE;F&_A_<N8
MF1]% E>']Y,U<V[5FKE8,,M;A/J["H&<]4*@NN=%3,KTSQD/F+U6^%.R\CER
M)6(U(#G+(I^85*\L%MT:Z?/+SL;+Q)W(3@,N+Z*NN W6DIQS[@$#%G;SM+3T
M:@<DO5@/MXY?+Z)+6(1R71"PZX7K=RN^W\:.7 K@K?\_'JY((]Q;1^6M?&F;
M!.975*B-@^J4"YB_#",02!Y2G[ [YL:*WV!:$X(;)G^$Y06( $R1QY9&<"]Q
M_M["G!?AJC*UZ?;(+^_*CETZE$0QGX4#$3 2Z#7Z 0']\F/$1&C$J):VR6;<
MF\&N72*SJF-WNO>86T4O7@<^KF^X+7N)#]]_U(>?"9?ZFL -,FZ%8M&P'<MZ
M)<[BS=@\T];N$\H;@BR]MV_QTC=/L?"01>GN::0C7KBE23P"MK)/DO(+CT@,
ME(E/Y;B(8=%%9_56_8ZW_Y]H[B:P&@/F?M%5)32$V!WB*TQ=]\0=Z3%?W.(0
M\>6D C.IOB1<@J-0+/!@Z$K Z(>QKVC 1"S]$9%4<=D?Z9YI!]$#O&FF,0$Y
MLQ4= QQ@:S :O^L+'Y!C/UQ/<,PDR^IN!CRG.(\6S6&UQ#H%%M.JBA7&IF16
MMLE-3(:PU %\BKB"2<'T>QRD"3^YYNJM)X3?H\!V!9./;*J4\OG#ATMA'C=R
M^8*UH\&F8X)!S Z*A#.E4IT8)BCO%%(YNE<BA951>W:)-$X[Q,E9)C1\0@)T
M9Y.WF;/8'1^?NL?^]:7V2OC<A;D*KL_!]H !\K]SD9T.B S3$2W*JYVG$'?-
MB.Q<*=]$8/.6F;1\D]F7)+.7$4,KB]7HNF 6/6%TT>\O#;J_%]F%@1GNS,@>
MM;MVWC.<O=[^>I*<M'V3Y1<LRRTI8Q;]R!*=8T9^SUU/HM.V;Q*]=#7GK%K-
MY4MEL[P3:EJ!AU/*\%2;JQ<UT/P+N1TP78-S;\4!ZQ<:$) 'A'A-KB-QJP8H
M&2&N0J@D'NOS("F,3<)+J_! ^?VTZCY']L85^SK('#?GNJ@VQ*):7$$F N;T
M#&?-8OX9L"ANTYXS@,T?1_CTZCY3:RZ9N$>V4\;=WNM>C:33US)OSZ4-WU 1
M0>OZ*_0(D\D/*B5?R  ,0.68#Y(.*A<(;8MCR70KF)DTSX '<[G6A>2 ',Z1
MQN6/$/DM!]0H!0$0"F\B=L,E] -%IH&+03AU72S'Q<;)(>W(DTF& >&'#YZ^
MV:.3<S>S^FF2WQ.V)___L3S;\WPG\Z8=0WK-C%[$Z!>#]L%$5*E_2T?R\#[
M'"#O4?<+S!LX.TQKB*CZKF+A[QA'&5','?S#H]+&A*2I,"0\V-7!PM5[&4>]
M6JO;/">.:3EZ-\,Y[#2O/IYUK\C%*;FX;';JW=9%.SD'>-IJU]N-5OV,-"[:
M)ZWNJG. .SS7LS)%NIAIJBM%04D\ OZ*@0Q2] @#WN.*5"JF#:*-[FA<LY><
MWYZ<B=6=\!2'G)%W'DS.L6M=P0UY<LY0)_WT&+A*#W3K]RCD:A QIG$%,,U$
MGY4"W=0:>,7 W^#. LE9R5$IW1"ZWH(J&;X07U+=4CK4DD"?3[6^P7@F[7ML
M). /1=UC$OFH_2S5M[H/HZ#\GA[D_<-9)MD=QW<'J0N<F^4V#$>[Z"@][S;=
M59N=TGV<KA[#Q_TX"K@<W#-#+>"C%G'--SD _Z/-8P^XPX#%.OD*-Z@!CG78
MYS[S]+5]J"<48(5",KUU/C%IY35#CP.<(3K44W] ]K!'BF>V=8IN?U+N? M&
ME\BX]Q?@0_*PG\]IC_L)*HV<*B(3>@Y@0%$Z-+XXLN4"CQ(#QC[-+R]-_8W#
M,[$8R9O;S7S%>D2&=IG87\\:5DS+3JWAU.;I<];GS79W?"CZM]:OK>[5UA9P
M6[(?A-6=R_YK:P8RK241XHQ4=[143;2KNLHB?*.SE2OVKQRS4+RW@U4P2X6%
M+:ST88JV)Y02PZIEXOEQ*7SND7>6_MEZEPN$)S5*RT3B"1"3'>A_;WA.Z?X^
M\0K&//.N;;%B.AM0]PS3MESHGS!=7?R8"MK*\;GJ5S-QH&^5\NN=.*SY0#>Z
M:F/](>8L1OV-1K-Y>GKX)"NUD[.5.MC!L&@]V7MD!%L*Y7:.8PNZ-S0T.R!\
M1<G384HARCU0.*\;=G@WJQFGIP"*DNF7??YD=Y7*/[8Y4,/)X#5^C[GIJ:/T
MHTJGZZ]8CK+TJ5B>NMC9 N6.UTE;4++>$FL+!.GJ3$-8M[[[E:KPAB[G:Q"^
M9AKXV<W\QB>[7J8 /(.I?F6\>GZ=Z Z2U:/^6.#.2O%X@,<IJX9=!LIGLP'Z
MP<Y7QYNC^W.]G\W"3P,FM%J<DC".CM<EZNA+SYODID62Q*_2'D0/L6*'CR'7
ML#4+,C5840*L6MWWQ]D B87J:?DZ.#.]"X"^/7F"#L]E.O.&#\%M\:&.,_3&
MQ/@Q#4,?[G&UCY^8G":94B#@.G5T6K22-.P,_&FR8@5\R?Z.-;PT\Q;22'$W
M]FE$O'3!M3*O^0KD<H<?$\,/_;7>M^O=CYWF"TUCS7[)+=GJ^COF41KLK9M^
M?6"/S(O]$7%IC/M:LPGF)%DJ@09X(9*/.?78@/I]3)HB()T@31O@7D$<0!\-
MCL9J("((^;V'$Z+;>8;G+;'-Y4WKZ[FW];92G7Q^WK$MK5+?W1*NM_I#9IOE
M!GYL7CZY4.N-7V_\^C[XA=_*]*ID86]U[;5&<8Y!7Y]GOXZJ:]-FES6;GI#(
MW9RNK,R2#^P&PL,SDS1$%-PRWW]QJO"")G)#\N[-):Y"OLY$+DSB 6D,..M#
M9#8^9GZACYDO?M7I&Q3ZI)BRZ<?J]??N:S_]'U!+ P04    " #%>UI7A@^2
MP=8"   ^"0  $0   '5T;60M,C R,S$P,C8N>'-DS55K;]HP%/V\_@J/+]FD
M)DY@= 4!556ZJAK;*O9HI6FJ3'P#UA([LQT>_WZV(3S*8U3:I/$%V_?<<\^)
M;VY:%],L16.0B@G>]J(@]!#P6%#&AVV/*>&?G]<;?N1==$Y:+WT?W4E!BQ@H
M&LS0=??FLJ\*I@$ID>@)D7"*+NF8< NX$EE>:)#HEG,Q)MH44*=F$P>G)I;/
M)!N.-'IU]1I5P_#<KX;5&OI^=_?POGYS__8LZH7?NF^N^M6;^Q\!FDPF = A
MD:Y:$(L,^;Y1I.(19 09#URUO9'6>1-C"Y[4 B&'V#!'^.%#[[/#>7-@LU#^
MD)!\F9 0-7#P10!;+24X8>D26&@RRH#:^@X3A=6S$D>!+7'3@4P#!7$P%&-L
M AN$TY3QG[O$1HU& [OH$FIXJ-ZD7=BJXWG00YK((>B/) .5DQB.$KLE89VZ
MAFUX0!2LZV '\(PK;2_=]$X*&7#]3LBL"PDI4J/^5T%2EC"@'B):2S8P7;$!
M*/@*TCEYT2*F8;1K&+,SVSQG/!%V_:)EI35+?7U(D'M@33W+H5U1+,M3J"S.
M1A*2=J70&?5+_X^YA,!X*B%2I"9MKR\;QB9%&4M.3V]5N*0@,MYBV;I00R)R
MD)J!6C[<"OXKCB@DSW5D4AAG_ZF?E R>Z\>D0/K/K%B*+T8\LHNO_=LEW:X7
M;"Z(4?G8%7%A7X7R_Y+3:ZZ9GMV:7I:9:Z<*8K1=.1KM1"U4K>ZP$YI?%"(?
ME<GK2\(IFC.A-:H6?DJR1ETHH)]XQZV?-O\B<0'9D[397T>EQ"2-B_1 F<5)
M>1EN,.#59##K]:'1,FTFI$;S[T-/Q"YP8(+9G5^.,=\>^5'5KT7!5)FQQ;>&
MZX$9B)]?OQSFMG!]7\F=T_]/Q=33:E1+;%]%V[%5W]BL16ZOCG*Z(WM#PA[5
MVY_"?5IWPNW"#0BG\7"]/=_R@_5VYF!(M2I/-JJW\)RM<_(;4$L#!!0    (
M ,5[6E>A<F.O%P(  "8'   5    =71M9"TR,#(S,3 R-E]D968N>&ULK95=
M;]HP%(:OX5=X[()-PG$21@<(J!!4"(U)B&EKI6F:0NP0:[&-;(>/?S_;)5!&
MNW4B-X"/7[_G.6\^Z-WN6 8V1"HJ>+\>>'X=$!X+3/FJ7Z=*P':[U8%!_790
M[;V!$,REP'E,,%CNP=UX,ERHG&H"E$CT-I*D 89X$W$K& FVSC618,JYV$3:
M-% -LXB]AME;[R5=I1J\&[T'H>^W8>B'3?!]/G_XU)K<?[P)9OZW\8?1(IS<
M__# =KOU"%Y%TG7S8L$ A(8HH_Q7UWXL(T6 &86K?BW5>MU%R)[9+67F";E"
MID43%<):M5)QVNY.T3/]MEFH _3P>?8E3@F+(.5*VYG<.46[RI5G(G9#O:(A
M>%%A5["005N"00B;@;=3^(29T.S8)==1R@BV&2";6>"'-R>EM?J_!"Y.'#((
M.IT.<KM/Q,8,ZZ/ZJ7<+/6Z>B^E?6(ZI#JJ5QPL9R5B*C"Q( @X_ORZFE]TH
MUPA3A@X:%&59#3C2KMZO2;^F*%MGI*BEDB0O8A38-OJ6#?VM=4/7(J6&0\;Y
MDD!3)=P^7"4B/N=^-?+1"F*21'FF2P2^]"X35["(EAGOA?7UL,X',L*61)9)
M>N9[PBP8_P1\[MV!'"'%\N=8Q+F97!??0X[ON*9Z/^6)D,R][/X-GVN&86'N
M*%_M?1K W":44UN<F>593[+3A&."BZX6O\P!#40/G?VO#*J_ 5!+ P04
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M<FO],2+7"ZU!(@(&(3*(H!LDD1()R(X.Q76H33"#*7*<(IVDC/3E(>/4446
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M"#:,Z)KTX70G;S!_S#^3G.[\"U!+ P04    " #%>UI7H2SHIM0U   )PP$
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MYGR=>>A9-IW@F'8K <CPL7>V$\QL*P6,1+0(XJBH*@%A8M&47^EJHJ!AG!?
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M6&+L'7_-JP30Q?QE)4H6;/?!,9FWG7'1J6A\R)WZ#G!H5,$ . ;<^];<I&V
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M>#A&*IDN[]%R+79#5LP8,>V15DMW&>"U6S#?S(-?2; P)[PJ,)S9/O"#"<Q
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MWES"VEB?D$B3XPI4XU7SXG\5US'Z>/DLU6:H7Z-2R@7(.!:$.U3[@Y9EAA_
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B9%]E>#DY>C$N:'1M4$L%!@     &  8 A $   %8      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
